Monoclonal antibodies targeting a variety of epitopes have been isolated from individuals
previously infected with SARS-CoV-2, but the relative contributions of these different …

Monoclonal antibodies targeting a variety of epitopes have been isolated from individuals
previously infected with SARS-CoV-2, but the relative contributions of these different …

Antibodies targeting the SARS-CoV-2 spike receptor-binding domain (RBD) are being
developed as therapeutics and are a major contributor to neutralizing antibody responses …

Monoclonal antibodies and antibody cocktails are a promising therapeutic and prophylaxis
for coronavirus disease 2019 (COVID-19). However, ongoing evolution of severe acute …

The evolution of SARS-CoV-2 could impair recognition of the virus by human antibody-
mediated immunity. To facilitate prospective surveillance for such evolution, we map how …

Many individuals mount nearly identical antibody responses to SARS-CoV-2. To gain insight
into how the viral spike (S) protein receptor-binding domain (RBD) might evolve in response …

Potent neutralizing monoclonal antibodies are one of the few agents currently available to
treat COVID-19. SARS-CoV-2 variants of concern (VOCs) that carry multiple mutations in the …

Many SARS-CoV-2 variants have mutations at key sites targeted by antibodies. However, it
is unknown if antibodies elicited by infection with these variants target the same or different …

The antiviral benefit of antibodies can be compromised by viral escape especially for rapidly
evolving viruses. Therefore, durable, effective antibodies must be both broad and potent to …

Since the COVID-19 pandemic onset, the antibody response to SARS-CoV-2 has been
extensively characterized. Antibodies to the receptor binding domain (RBD) on the spike …